Solésence, Inc. (SLSN) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Solésence, Inc. is a science-driven consumer health company focused on skin health products utilizing proprietary technologies (Active Stress Defense™, Blüm™, Chromalüm™, WHSPR™) for sun care, skin care, and cosmetics. The company operates as a single segment and is classified as a smaller reporting company. As of August 19, 2026, there were 70,647,045 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 (Restated) | YTD 2026 | YTD 2025 (Restated) |
|---|---|---|---|---|
| Total Revenue | $15,332 | $20,359 | $28,290 | $34,984 |
| Gross Profit | $4,748 | $6,443 | $7,890 | $10,089 |
| Gross Margin | 31.0% | 31.6% | 27.9% | 28.8% |
| Net Income (Loss) | $(158) | $3,233 | $(1,120) | $3,577 |
| Operating Cash Flow (YTD) | $1,708 | $(7,875) | $1,708 | $(7,875) |
| Cash and Equivalents | $1,046 | $4,108 | $1,046 | $4,108 |
| Total Debt (Related Party) | $14,287 | $15,267 | $14,287 | $15,267 |
Note: 2025 figures have been restated due to inventory accounting errors (see Material Changes).
Material Changes and Restatement
Restatement of Prior Periods: The company identified errors in historical inventory accounting regarding the allocation of labor and overhead costs. Consequently, financial statements for periods ending through March 31, 2026, have been restated.
- Inventory Impact: Inventories were overstated. As of December 31, 2025, inventory was reduced by $3,548,000.
- Profit Impact: Cost of revenue was adjusted, resulting in higher reported net income for Q2 2025 (restated from $2,667k to $3,233k) and Q1 2026 (restated loss from $(766)k to $(962)k).
Operational Changes:
- Revenue Decline: Revenue decreased 24.7% in Q2 2026 compared to the prior year, primarily due to the completion of a new customer launch in 2025 that drove higher sales in the prior period.
- Customer Concentration: Three customers accounted for 66% of revenue in Q2 2026. Customer #1 (Consumer Products) grew its share from 33% in 2025 to 58% in 2026.
- Settlement Liability: A $938,000 settlement liability was recognized in Q2 2026 related to a dispute with Refy Beauty Ltd, classified as a general and administrative expense.
Outlook, Risks, and Contingencies
Management Commentary:
- Liquidity: The company generated positive operating cash flow of $1.7 million YTD 2026, a significant improvement over the prior year. Capital expenditures for 2026 are expected to range between $0.5 million and $1.5 million.
- Debt Structure: The company relies heavily on related-party debt (Beachcorp, LLC and Strandler, LLC) totaling approximately $14.3 million. These facilities mature in April 2027. A waiver was obtained in August 2026 regarding inventory overstatement breaches under the Inventory Facility.
Risks and Contingencies:
- Internal Controls: The company disclosed a material weakness in internal controls over financial reporting related to inventory costing. Remediation is underway.
- Customer Risk: Exclusive supply agreements with BASF contain contingencies that could force the sale of production equipment if performance requirements are not met.
- Legal: The Refy Beauty settlement requires payments of $938,000 over 12 months, though the final six payments may be credited against future product purchases if a new commercial agreement is reached.
Investor Verification Checklist
- Restatement Details: Verify the full impact of the inventory accounting restatement on future quarters and the timeline for filing amended 10-K and 10-Q reports.
- Debt Renewal: Confirm the company's ability to refinance or extend the $14.3 million in related-party debt maturing in April 2027.
- Customer Concentration: Assess the stability of Customer #1, which now represents 58% of quarterly revenue.
- Internal Controls: Monitor progress on remediation of the material weakness regarding inventory cost allocation.
- Refy Settlement: Track whether the exclusivity period results in a new commercial agreement to offset the remaining settlement payments.